In addition to its ability to inhibit CDK1 and CDK2, dinaciclib abrogates CDK12 activity and suppresses the expression of BRCA1, BRCA2, and Rad5, thereby sensitizing BRCA-wild type triple negative breast cancer to PARP inhibition (93). This evidence concerns the gene CDK2 and triple-negative breast carcinoma.